Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q15717
UPID:
ELAV1_HUMAN
Alternative names:
Hu-antigen R
Alternative UPACC:
Q15717; B4DVB8; Q53XN6; Q9BTT1
Background:
ELAV-like protein 1, also known as Hu-antigen R, plays a crucial role in RNA-binding, specifically targeting the 3'-UTR region of mRNAs to enhance their stability. This protein is pivotal in embryonic stem cell differentiation, binding to mRNAs not methylated by N6-methyladenosine (m6A), thus stabilizing them. It also interacts with m6A-containing mRNAs, including those of MYC, contributing to MYC stability. ELAV-like protein 1 binds to poly-U elements and AU-rich elements in the 3'-UTR of target mRNAs, significantly influencing the expression of genes like FOS and IL3.
Therapeutic significance:
Understanding the role of ELAV-like protein 1 could open doors to potential therapeutic strategies.